http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

A good 8% pull back today.

And another 10%

Summit Receives Regulatory Approval to Start Ph...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT RECEIVES REGULATORY APPROVAL TO START PHASE 1B CLINICAL TRIAL OF SMT C1100 IN DMD PATIENTS

Oxford, UK, 1 November 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announces that its Phase 1b Clinical Trial Application for SMT C1100 has received approval from the UK Medicines and Healthcare products Regulatory Agency ('MHRA') and the Ethics Review Committee. SMT C1100 is a small molecule utrophin modulator that has the potential to treat all patients with DMD, regardless of the underlying genetic fault.

"Securing regulatory approval for the first in patient Phase 1b clinical trial has achieved another important milestone in the development of utrophin modulator, SMT C1100, for DMD," commented Glyn Edwards, Chief Executive Officer. "We believe that utrophin modulation is a novel disease-modifying approach for all boys with DMD and this Phase 1b trial forms an integral part of our wider clinical plans towards establishing SMT C1100 as a viable treatment for this devastating condition."

The Phase 1b trial will be a dose-escalating, open-label study and will be conducted in a total of 12 paediatric patients with DMD, aged between 5 and 11 years. It will evaluate the safety and tolerability of SMT C1100, and will measure blood concentration levels of the drug as Summit aims to confirm the dose to be used in a subsequent patient proof of concept efficacy trial. The Phase 1b trial will be conducted at up to four NHS hospitals located in the UK and patient recruitment is expected to start shortly.

The Chief Investigator for the trial, Professor Francesco Muntoni, Paediatric Neurologist at Great Ormond Street Hospital and Director of the Dubowitz Neuromuscular Centreadded, "Utrophin is a promising approach for the treatment of all DMD patients, regardless of their genetic mutation. It also has the potential to be complementary to other therapeutics approaches in clinical development and the start of the first patient trial of SMT C1100 is an important moment for the whole DMD community."

Further details about the clinical trial will be made available via www.clinicaltrials.gov and www.clinicaltrialsregister.eu.

- END -

Sounds promising!

1 Nov N+1 Singer 11.00 Buy

Shares in drug developer Summit Corporation (LON:SUMM) may not have got the shot in the arm it was hoping for, but twice the normal number of shares traded changed hands on the day.

Summit received UK regulatory approval to start patient trials of its SMT C1100 drug.

SMT C1100 is being developed for use in the treatment of the fatal muscle wasting disease Duchenne Muscular Dystrophy (DMD). It has the potential to treat all patients with DMD, regardless of the underlying genetic fault.

The Phase 1b trial will be a dose-escalating, open-label study and will be conducted in a total of 12 paediatric patients with DMD, aged between 5 and 11 years.

The study will evaluate the safety and tolerability of SMT C1100, and will measure blood concentration levels of the drug as Summit aims to confirm the dose to be used in a subsequent patient proof of concept efficacy trial.



http://www.proactiveinvestors.co.uk/companies/market_reports/62824/proactive-news-summary-falcon-oil-gas-summit-corporation-metminco-fastjet-rurelec-0000.html

Summit and Joining Jack Enter Funding Agreement...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT AND JOINING JACK ENTER FUNDING AGREEMENT TO SUPPORT DEVELOPMENT OF NOVEL BIOMARKERS FOR DMD

Oxford, UK, 5 November 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, is pleased to announce it has entered into a funding agreement with the UK charity, Joining Jack, to support the development of novel biomarkers for DMD.

Summit aims to develop new biomarkers that are both related to the mechanism of its utrophin modulator candidate SMT C1100 and to other aspects of muscle health, including muscle fibre regeneration and inflammation. The information gained from this effort will support the clinical development of SMT C1100 and other therapeutic candidates for the treatment of DMD. Joining Jack were formed in 2012 to support research into identifying therapies for DMD and they will provide up to £100,000 in funding to support this development effort.

"Summit is delighted to enter this agreement with Joining Jack to support our development programme to create novel and meaningful biomarkers to help determine the impact of new candidates like SMT C1100 in clinical trials and to supplement the existing endpoints, which are often seen as limited and challenging," commented Glyn Edwards, Chief Executive Officer of Summit. "We are grateful for the continuing support of the DMD community in advancing this therapeutic approach which could potentially treat all patients with DMD, regardless of the underlying genetic cause."

Andrew Johnson from Joining Jack added: "Our mission is to provide support for potential new therapies in DMD to ultimately ensure that we can make a difference for this generation of boys suffering from this disease. We believe that SMT C1100 and the utrophin modulation approach holds significant promise."

The biomarker development work will be conducted in collaboration with the leading research groups of Dr Jenny Morgan, Professor Caroline Sewry and Professor Francesco Muntoni at the Institute of Child Health, University College London.

- END -

N+1 Singer Buy 10.13 10.13 11.00 16.30 Reiterates

Summit and the University of Oxford Enter Strategic Alliance to Develop Treatments for DMD

SUMMIT AND THE UNIVERSITY OF OXFORD ENTER STRATEGIC ALLIANCE TO DEVELOP TREATMENTS FOR DUCHENNE MUSCULAR DYSTROPHY


Summit acquires exclusive rights to a pipeline of novel utrophin modulators and core technology, and an exclusive option to intellectual property arising from the research collaboration

Technology acquired through issue of up to 42.5 million new ordinary shares

WATCH: Summit Corporation CEO Glyn Edwards and Prof Kay Davies talk about a strategic alliance in Duchenne Muscular Dystrophy

Click here to watch

UPDATE - Summit seals exclusive deal with Oxford University that underpins its DMD programme
By Ian Lyall November 25 2013, 4:27pm The all-paper deal with Oxford University will see it issue it issue 42.5mln shares, worth just over £3.9mln as of Friday’s close.The all-paper deal with Oxford University will see it issue it issue 42.5mln shares, worth just over £3.9mln as of Friday’s close.

---ADDS FURTHER CEO COMMENTS AND SHARE PRICE---

Shares in drug developer Summit (LON:SUMM) advanced around 10% on Monday after unveiling a deal to acquire a pipeline of new utrophin modulators, the technology at the core of its treatment for Duchenne Muscular Dystrophy (DMD).

The all-paper deal with Oxford University will see it issue 42.5mln shares, worth just over £3.9mln as of Friday’s close.

These assets have been developed at the university by research teams led by Professor Kay Davies, an internationally acclaimed expert in DMD; Professor Stephen Davies, the Waynflete Professor of Chemistry; and Dr Angela Russell, an expert in medicinal chemistry and pharmacology.

As part of the collaboration, Summit will sponsor a drug discovery programme to identify and develop additional utrophin modulator drugs.

Davies, a co-founder and former director of Summit, is re-joining the board a non-executive director following the deal.

Chief executive Glyn Edwards said: “The alliance provides access to differentiated classes of utrophin modulators, potentially with new mechanisms, to complement our clinical candidate SMT C1100, while also establishing a strong drug pipeline for the future.

“Importantly, it will help to cement our long-term relationship with the scientific leaders in the field at the University of Oxford."

DMD is a rare but fatal muscle wasting disease that occurs in boys.

Utrophin is at the heart of Summit’s drug candidate C1100 and it is thought to act in a similar way to dystrophin, which regulates muscle tone and function.

Edwards, in a video presentation, said it was important to bring through the next generation of compounds - and the tie-up with Oxford would do this.

"For while C1100 is the pathfinder, and we believe will revolutionise the treatment of Duchenne Muscular Dystrophy, we can already see ways of improving on that," he told investors.

"It is quite common when there are medical breakthroughs to have a first-in-class compound that gets to market first and moves the treatment forward hugely.

"But we can already see ways of improving on C1100 by working with the thought leaders at the University of Oxford."

The reaction to the tie-up was a positive one with the shares rising 10% to 10.12p a share, valuing the business at £46mln

Just starting to look positive again.

Summit Announces First Patient Dosed in a Phase 1b Clinical Trial of SMT C1100

The Chancellor Masters and Scholars of the University of Oxford > 3%

Has anyone any news about Summit?

:-))

On the up again +11%.

Up another 9%.

Sarepta DMD trial results buoy Summit

By Jamie Nimmo

January 16 2014, 4:37pm
Sarepta and Summit are both working towards a treatment for DMD, a rare but fatal muscle-wasting disease



The latest trial results from America’s Sarepta Therapeutics bode well for AIM-listed Summit (LON:SUMM).

That’s because the pair are both working towards a treatment for Duchenne Muscular Dystrophy (DMD), a fatal muscle-wasting disease that affects boys.

Sarepta revealed at the JPMorgan Healthcare Conference in San Francisco that Eteplirsen trial patients showed continued stability when walking as part of the ongoing Phase IIb study.

Sufferers on the drug were able to walk further than the group of patients given the placebo, confirming the benefits of the drug.

Summit may look like a minnow alongside Sarepta and its $1 billion market capitalisation. But that’s only after a two-year surge that has seen Sarepta’s share price jump from 60 cents to $26.90 – it jumped another 35% today.

Summit, which rose 8% to 12.7p on the back of the news, treated its first patient suffering from DMD last month as part of a phase Ib clinical trial of its own treatment, SMT C1100.

Richard Pye, head of corporate development and communications at Summit, explained that Eteplirsen will only treat 13% of DMD boys since it is specific to a genetic form.

Summit’s treatment meanwhile would treat all sufferers.

Pye says that because of the difference in approach between the two companies, he sees Sarepta less as a rival and more as “complimentary”.

“There is progress being made and there is a better understanding from a clinical trial perspective as to what’s going on and what effect they are seeing in patients. That helps us when we get to do our clinical studies as well,” he said.

“Having an approach that enables us to target all the boys irrespective of the genetic mutation they’ve got puts us in a really strong position.”

Summit’s trial involves twelve boys aged between five and eleven years and is taking place at up to four NHS hospitals in the UK.

this stock has been on the rocks for some time, jam tomorrow? maybe one day